Orthocell Ltd (AU:OCC) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Orthocell Ltd has achieved a second consecutive quarter of record revenue, reaching $2.03 million, driven by the success of its products Striate+ and Remplir. The company has also received significant regulatory approvals for market expansion into Singapore and Canada, bolstering its global presence. With a strong cash position, Orthocell is poised to accelerate its market access strategy in new regions, aiming to become a key player in the $4 billion global market.
For further insights into AU:OCC stock, check out TipRanks’ Stock Analysis page.